Tradestie Institutional Equity Comparison Engine

DSGN vs CRMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while DSGN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DSGN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRMD at 29.5x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (90th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
DSGN N/M vs CRMD 29.5x Fwd P/E
Growth & Margin Winner CRMD
Op Margin 0.0% vs 41.0% ยท YoY +0.0% vs -47.7%
Momentum & Technical Winner DSGN
1Y +33.5% vs -58.5% ยท 52W Pos 29% vs 0%
Options & Structure Winner DSGN
BREAKDOWN (13th %ile IV) vs BREAKDOWN (90th %ile IV)
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.84
-0.81% 1D
Market Cap $670.5M
1M Return -7.52%
1Y Return +33.51%
Forward P/E N/M
Unified AI Score
45.6 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 60.0 Mom 64.0
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.67
-3.11% 1D
Market Cap $370.6M
1M Return -36.72%
1Y Return -58.45%
Forward P/E 29.5x
Unified AI Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DSGN +33.51% CRMD -58.45% Spread: +91.96 pp (DSGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DSGN Revenue CRMD Revenue DSGN Op. Margin CRMD Op. Margin Margin Edge
FY2017 N/A $0M N/A -9997.4% CRMD
FY2018 N/A $0M N/A -6250.4% CRMD
FY2019 N/A $0M N/A -7416.3% CRMD
FY2020 $0M $0M -3685.8% -11378.4% DSGN
FY2021 N/A $0M N/A -15417.5% CRMD
FY2022 N/A $0M N/A -46819.9% CRMD
FY2024 N/A $40M N/A -51.4% CRMD
FY2025 N/A $310M N/A 48.2% CRMD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DSGN (4) vs CRMD (6)
Institutional Metric DSGN CRMD Criterion Row Winner
Market Capitalization Scale $670.5M $370.6M Larger Scale DSGN
Trailing P/E Ratio Valuation N/M 2.4x Lower Multiple CRMD
Forward P/E Ratio Valuation N/M 29.5x Lower Multiple CRMD
Revenue Growth (YoY) Growth +0.0% -47.7% Higher Growth DSGN
Operating Margin (TTM) Profitability 0.0% 41.0% Higher Margin CRMD
Net Profit Margin Profitability 0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency -36.9% 15.3% Higher ROE CRMD
52-Week Range Position Momentum 29% ($7โ€“$17) 0% ($5โ€“$13) Stronger Trend DSGN
Beta / 30D Volatility Risk Regime 1.32ฮฒ ยท 60% Vol 1.22ฮฒ ยท 103% Vol Lower Realized Risk DSGN
Unified Institutional Score Composite Signal 45.6 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DSGN vs CRMD Buy Guide
DSGN BREAKDOWN
140d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DSGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 90th %ile
IV Regime Extreme (>80th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DSGN nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.